Senior Medical Director, Pharmacovigilance

Role Overview & Key Functions:

The Medical Director, Pharmacovigilance (PV) will provide broad support of activities requiring medical safety input for assigned products, pre- and post-approval. He/she will support and/or lead periodic safety signaling reviews and meetings, as well as perform individual and aggregate case review. He/she will also participate, in varying degrees, on clinical teams/programs and other intra and/or inter-departmental activities and initiatives.

 

RESPONSIBILITIES:

 

• Represent department as medical safety lead on cross-functional study and program teams for assigned products and studies, providing expert guidance regarding safety matters and issues.
• Provide timely and sound medical review of individual case safety reports from clinical trials or post-marketing sources as needed.
• Participate in protocol development, specifically the monitoring and collection of safety information in clinical trial protocols, as well as statistical analysis plans.
• Participate in the analysis of safety data from on-going and completed clinical trials and representation in Clinical Study Reports.
• Contribute to preparation and review of periodic reports (IND, Annual Safety, DSUR, PBRERs,).
• Review and provide medical content, as needed, for key study-related documents, e.g. protocols, IB, ICF, IDMC Charter.
• Participate in departmental development activities including SOP and Work Instructions development.
• Provide guidance to staff regarding optimal practice regarding collection, evaluation and processing of adverse experience reports, from a medical perspective.
• Provide a contributory role in Partner /Affiliate agreements and interactions, as needed.
• As directed by the PV Head, assume primary responsibility/chair for the conduct of one or more Safety Team(s) for assigned products.
• Participate in the regular review of safety data for assigned products for the identification of new safety signals, in accordance with signal detection practices.
• Participate in Risk Management Strategy.
• Other activities, as needed or as requested by manager.

Candidate Profile & Requirements:

• MD, DO or MBBS.
• Minimum of 15 years Drug Safety/Pharmacovigilance
• Solid knowledge of General Medicine
• Residency training preferred
• Adequate knowledge of GCP, ICH and Global regulations.
• Prior NDA experience and oncology experience preferred.
• Knowledge of principles of epidemiology and statistics required
• Experienced in the evaluation and interpretation of data.
• Ability to multi-task.
• Solid written and oral communication skills.
• Solid judgment and decision-making skills, including the identification and communication of relevant safety- related issues or concerns to Medical Safety Management in an appropriate and timely manner.
• Experienced in safety reviews of AEs/SAEs, IBs, protocols, clinical study reports, informed consents, and other safety-related documents

 

At Karyopharm, base pay is one part of a competitive total rewards package that includes comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses. Actual pay is based on factors such as location, experience, skills, education, and internal equity. We maintain broad salary ranges to reflect market conditions and the specialized nature of our work. The anticipated base salary range for this position is $310 K - $380 K USD. 

Our Value Proposition:

This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs. 

 

Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S. We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.  

 

As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology. We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued. 

 

Learn more at Karyopharm Therapeutics.